An open label, pilot and expansion pharmacodynamic Study of (Z)-endoxifen in Patients with Invasive Breast Cancer Prior to Undergoing Mastectomy or Lumpectomy.
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
Price : $35 *
At a glance
- Drugs Endoxifen (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- Sponsors Atossa Genetics
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.
- 17 Jul 2018 New trial record
- 13 Jul 2018 According to an Atossa Genetics media release, the CPR Pharma Services, a CRO is a sponsorer of the study